www.fdanews.com/articles/197627-sinovac-says-covid-19-vaccine-generated-immune-response
Sinovac Says COVID-19 Vaccine Generated Immune Response
June 16, 2020
Sinovac’s COVID-19 vaccine candidate induced an immune response, according to preliminary data from its phase 1/2 trial.
The Chinese drugmaker said the phase 2 portion of the trial showed the vaccine, called CoronaVac, induced neutralizing antibodies in 90 percent of participants 14 days after vaccination.
Sinovac said it will advance the vaccine to a phase 3 study “in the near future.”